CME vs Nasdaq
CME and NDAQ side by side, both in security & commodity brokers, dealers, exchanges & services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CME and NDAQ compare
CME is the larger company, worth 1.8 times as much as Nasdaq ($109B against $59.4B).
On earnings, CME is cheaper: it trades at 25.7× trailing earnings, against 31.0× for Nasdaq.
Nasdaq grew revenue faster over the last twelve months (7.7% versus 5.1% for CME).
Both pay dividends: CME yields 3.7% and Nasdaq 1.1%.
Nasdaq scores higher on the StockData Score (18 against 9 for CME), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CME | NDAQ |
|---|---|---|
| Size and price | ||
| Market cap | $109B | $59.4B |
| Share price | $303.14 | $106.23 |
| Change, 1 year | 15.9% | 24.4% |
| Change, 5 years | 36.7% | 49.7% |
| Beta (5Y) | 0.36 | 0.89 |
| Employees | 3,875 | 9,525 |
| StockData Score | ||
| Total score | 9 | 18 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 4 (better) |
| Performance score | 2 | 5 (better) |
| Health score | 5 | 5 |
| Dividend score | 1 | 4 (better) |
| Valuation | ||
| P/E | 25.7× (better) | 31.0× |
| P/S | 16.1× | 6.8× (better) |
| P/B | 4.1× (better) | 5.0× |
| EV/EBITDA | 24.2× (better) | 24.6× |
| P/FCF | 25.9× (better) | 30.4× |
| PEG | 1.75 (better) | 2.82 |
| FCF yield | 3.9% (better) | 3.3% |
| Fair value | $250.81 | $79.91 |
| Margin of safety | −20.9% (better) | −32.9% |
| Growth | ||
| Revenue growth (TTM) | 5.1% | 7.7% (better) |
| Revenue growth, 5Y average | 6.0% | 8.0% (better) |
| Net income growth (TTM) | – | 30.4% |
| EPS growth (TTM) | 14.1% | 31.9% (better) |
| EPS growth, 5Y average | 13.7% (better) | 10.7% |
| Profitability | ||
| Gross margin | – | 64.2% |
| Operating margin | 65.1% (better) | 29.5% |
| Net margin | – | 22.5% |
| FCF margin | 62.2% (better) | 22.3% |
| Return on equity | – | 16.5% |
| Return on invested capital | 13.5% (better) | 10.3% |
| Financial health | ||
| Debt / equity | 0.00 | 0.73 (better) |
| Net debt / EBITDA | – | 3.00 |
| Interest coverage | – | 7.4× |
| Current ratio | 1.02 (better) | 1.01 |
| Altman Z-score | 0.56 | 3.48 (better) |
| Piotroski F-score | 5 | 9 (better) |
| Dividends and buybacks | ||
| Dividend yield | 3.7% (better) | 1.1% |
| Payout ratio | – | 32.3% |
| Years of dividend growth | 0 | 13 (better) |
| Dividend growth, 5Y average | −3.3% | 10.1% (better) |
| Buyback yield | – | 2.2% |
| Shareholder yield | 3.7% (better) | 3.3% |
| Ownership | ||
| Held by institutions | 89.5% | 84.7% |
| Held by insiders | 0.34% | 18.9% |
| Insider net buying, 12 months | −$30.4M (better) | −$65.1M |
| Superinvestors holding | 5 (better) | 1 |
| Short interest, % of float | 1.5% | 1.7% |
Go deeper
- CME stock overview
- CME income statement
- CME valuation and score
- NDAQ stock overview
- NDAQ income statement
- NDAQ valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.